CXM Financial Facts
Research and development: 108.67KInterest expense: -2.11K
See Full Income Statement
Total stockholders' equity: -3.36M
Total liabilities: 3.41M
See Full Balance Sheet
Cardium Therapeutics, Inc. (CXM) Earnings
|
Expand Research on CXM
| Next EPS Date | 6/4/24 | EPS Growth Rate | +16.7% |
|---|---|---|---|
| Average EPS % Beat Rate | +179.0% | Revenue Growth Rate | +12.1% |
| Average % Move 1-Wk after EPS | -9.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6/4/24 | Q125 | N/A | $0.07 | N/A | N/A | $194.37M | = | N/A | N/A | ||
| 3/27/24 | Q424 | $0.13 | $0.09 | +$0.04 | $194.2M | $188.75M | = |  | | Details | |
| 12/6/23 | Q324 | $0.12 | $0.07 | +$0.05 | $186.3M | $180.42M | = | | | Details | |
| 9/6/23 | Q224 | $0.10 | $0.05 | +$0.05 | $178.5M | $173.45M | = | | | Details | |
| 6/5/23 | Q124 | $0.06 | $0.01 | +$0.05 | $173.4M | $169M | = | | | Details | |
| 3/29/23 | Q423 | $0.06 | $0.02 | +$0.04 | $165.3M | $162.78M | = | | | Details | |
| 12/6/22 | Q323 | $0.02 | -$0.01 | +$0.03 | $157.25M | $156.05M | = | | | Details | |
| 9/8/22 | Q222 | -$0.09 | -$0.06 | -$0.03 | $118.69M | $147.46M | = | | | Details |
